Vanguard Group’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $84.4M | Buy |
2,048,452
+406,254
| +25% | +$15.7M | ﹤0.01% | 1942 |
|
|
2025
Q3 | $64.6M | Buy |
1,642,198
+196,117
| +14% | +$5.01M | ﹤0.01% | 2038 |
|
|
2025
Q2 | $26.9M | Buy |
1,446,081
+337,206
| +30% | +$6.33M | ﹤0.01% | 2415 |
|
|
2025
Q1 | $20.1M | Sell |
1,108,875
-165,763
| -13% | -$3.65M | ﹤0.01% | 2497 |
|
|
2024
Q4 | $27.8M | Sell |
1,274,638
-20,331
| -2% | -$523K | ﹤0.01% | 2424 |
|
|
2024
Q3 | $35.5M | Buy |
1,294,969
+49,741
| +4% | +$1.39M | ﹤0.01% | 2323 |
|
|
2024
Q2 | $32.2M | Buy |
1,245,228
+707,400
| +132% | +$17M | ﹤0.01% | 2332 |
|
|
2024
Q1 | $16.1M | Buy |
537,828
+384,182
| +250% | +$8.35M | ﹤0.01% | 2705 |
|
|
2023
Q4 | $1.6M | Buy |
153,646
+26,769
| +21% | +$296K | ﹤0.01% | 3678 |
|
|
2023
Q3 | $1.73M | Buy |
126,877
+3,851
| +3% | +$48.5K | ﹤0.01% | 3638 |
|
|
2023
Q2 | $1.49M | Hold |
123,026
| – | – | ﹤0.01% | 3764 |
|
|
2023
Q1 | $1.56M | Buy |
123,026
+261
| +0.2% | +$2.89K | ﹤0.01% | 3767 |
|
|
2022
Q4 | $776K | Buy |
122,765
+50
| +0% | +$885 | ﹤0.01% | 3989 |
|
|
2022
Q3 | $2.77M | Buy |
122,715
+3,479
| +3% | +$95.2K | ﹤0.01% | 3612 |
|
|
2022
Q2 | $2.29M | Buy |
119,236
+3,003
| +3% | +$74.2K | ﹤0.01% | 3749 |
|
|
2022
Q1 | $5.39M | Sell |
116,233
-4,595
| -4% | -$251K | ﹤0.01% | 3491 |
|
|
2021
Q4 | $8.56M | Sell |
120,828
-9,903
| -8% | -$995K | ﹤0.01% | 3308 |
|
|
2021
Q3 | $15.2M | Buy |
130,731
+34,244
| +35% | +$3.99M | ﹤0.01% | 3007 |
|
|
2021
Q2 | $15.1M | Buy |
96,487
+7,520
| +8% | +$1.38M | ﹤0.01% | 2992 |
|
|
2021
Q1 | $16.9M | Buy |
88,967
+6,374
| +8% | +$1.07M | ﹤0.01% | 2871 |
|
|
2020
Q4 | $10.4M | Buy |
82,593
+8,467
| +11% | +$960K | ﹤0.01% | 2972 |
|
|
2020
Q3 | $8.06M | Buy |
74,126
+754
| +1% | +$89.3K | ﹤0.01% | 2889 |
|
|
2020
Q2 | $8.82M | Buy |
73,372
+17,608
| +32% | +$2.48M | ﹤0.01% | 2839 |
|
|
2020
Q1 | $5.6M | Buy |
55,764
+684
| +1% | +$127K | ﹤0.01% | 2926 |
|
|
2019
Q4 | $13.4M | Sell |
55,080
-156
| -0.3% | -$29.2K | ﹤0.01% | 2720 |
|
|
2019
Q3 | $9.07M | Sell |
55,236
-36
| -0.1% | -$6.84K | ﹤0.01% | 2864 |
|
|
2019
Q2 | $13M | Buy |
55,272
+23,759
| +75% | +$5.87M | ﹤0.01% | 2709 |
|
|
2019
Q1 | $8.3M | Buy |
31,513
+22,854
| +264% | +$3.94M | ﹤0.01% | 2920 |
|
|
2018
Q4 | $790K | Sell |
8,659
-370
| -4% | -$50.4K | ﹤0.01% | 3633 |
|
|
2018
Q3 | $1.74M | Buy |
9,029
+4,341
| +93% | +$914K | ﹤0.01% | 3577 |
|
|
2018
Q2 | $1.01M | Buy |
+4,688
| New | +$1.06M | ﹤0.01% | 3685 |
|
Other funds holding DNTH
Vanguard Group's DNTH Position: Q4 2025 in Review
Vanguard Group increased its Dianthus Therapeutics (DNTH) stake by 25% in Q4 2025, buying an estimated $15.7M and bringing the position to 2,048,452 shares worth $84.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1942.
Vanguard Group first reported a position in DNTH in Q2 2018 and has held it in 31 quarters since. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.
- Vanguard Group held 2,048,452 shares of Dianthus Therapeutics worth $84.4M as of Q4 2025.
- Vanguard Group bought 406,254 Dianthus Therapeutics shares in Q4 2025, an estimated $15.7M.
- Dianthus Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1942 holding.
- Vanguard Group first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 31 quarters since.
- 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.